Page 113 - 《中国药房》2023年8期

944-947. [34] WATSON P G. Latanoprost. Two years’ experience of its
[30] STAMER W D，ACOTT T S. Current understanding of use in the United Kingdom. Latanoprost Study Group[J].
conventional outflow dysfunction in glaucoma[J]. Curr Ophthalmology，1998，105（1）：82-87.
Opin Ophthalmol，2012，23（2）：135-143. [35] ABELSON M B，MROZ M，ROSNER S A，et al. Multi‐
[31] SHARIF N A，KELLY C R，CRIDER J Y，et al. Ocular center，open-label evaluation of hyperemia associated
hypotensive FP prostaglandin（PG）analogs：PG receptor with use of bimatoprost in adults with open-angle glau‐
subtype binding affinities and selectivities，and agonist coma or ocular hypertension[J]. Adv Ther，2003，20（1）：
potencies at FP and other PG receptors in cultured cells[J]. 1-13.
J Ocul Pharmacol Ther，2003，19（6）：501-515. [36] HUANG A S，MEYER J J. Bimatoprost ophthalmic solu‐
[32] WANG J W，WOODWARD D F，STAMER W D. Dif- tion [M/OL].Treasure Island（FL）：StatPearls Publishing，
ferential effects of prostaglandin E2-sensitive receptors on 2022 [2022-03-08]. https：//www.ncbi.nlm.nih.gov/books/
contractility of human ocular cells that regulate conven‐ NBK576421/.
tional outflow[J]. Invest Ophthalmol Vis Sci，2013，54 [37] RICAR J，CETKOVSKA P，HORDINSKY M，et al. Topi‐
（7）：4782-4790. cal bimatoprost in the treatment of eyelash loss in alopecia
[33] CHEN J E，DINH T，WOODWARD D F，et al. Bimato‐ totalis and universalis：a prospective，open-label study[J].
prost：mechanism of ocular surface hyperemia associated Dermatol Ther，2022，35（6）：e15438.
with topical therapy[J]. Cardiovasc Drug Rev，2005，23 （收稿日期：2022-08-14 修回日期：2023-02-09）
（3）：231-246. （编辑：陈 宏）

（上接第987页）
[11] 张翔云，杜闪闪，祖冬妮，等. 托伐普坦治疗低钠血症疗 [17] SHEA B J，REEVES B C，WELLS G，et al. AMSTAR 2：a
效及安全性的 Meta 分析[J]. 重庆医科大学学报，2016， critical appraisal tool for systematic reviews that include
41（9）：964-970. randomised or non-randomised studies of healthcare inter‐
[12] BHANDARI S，PERI A，CRANSTON I，et al. A systematic ventions，or both[J]. BMJ，2017，358：j4008.
review of known interventions for the treatment of chronic [18] ATKINS D，BEST D，BRISS P A，et al. Grading quality of
nonhypovolaemic hypotonic hyponatraemia and a meta- evidence and strength of recommendations[J]. BMJ，2004，
analysis of the vaptans[J]. Clin Endocrinol（Oxf），2017，86 328（7454）：1490.
（6）：761-771. [19] STERNS R H. Adverse consequences of overly-rapid cor‐
[13] LI B L，FANG D，QIAN C，et al. Erratum to：the efficacy rection of hyponatremia[J]. Front Horm Res，2019，52：
and safety of tolvaptan in patients with hyponatremia：a 130-142.
meta-analysis of randomized controlled trials[J]. Clin [20] TORRES V E，CHAPMAN A B，DEVUYST O，et al.
Drug Investig，2017，37（4）：411-413. Tolvaptan in patients with autosomal dominant polycystic
[14] HUNT H，POLLOCK A，CAMPBELL P，et al. An intro‐ kidney disease[J]. N Engl J Med，2012，367（25）：2407-
duction to overviews of reviews：planning a relevant 2418.
research question and objective for an overview[J]. Syst [21] US Food and Drug Administration. FDA drug safety com‐
Rev，2018，7（1）：39. munication：FDA limits duration and usage of samsca
[15] PAGE M J，MCKENZIE J E，BOSSUYT P M，et al. The （tolvaptan）due to possible liver injury leading to organ
PRISMA 2020 statement：an updated guideline for reporting transplant or death[EB/OL].（2013-04-30）[2022-07-18].
systematic reviews[J]. J Clin Epidemiol，2021，134： https：//www.fda.gov/drugs/drug-safety-and-availability/
178-189. fda-drug-safety-communication-fda-limits-duration-and-
[16] 王靖，刘琴，翁淳光，等. 国内公共卫生研究领域系统评 usage-samsca-tolvaptan-due-possible-liver.
价/Meta 分析的质量评价[J]. 中国循证医学杂志，2010， （收稿日期：2022-08-20 修回日期：2023-02-28）
10（12）：1367-1374. （编辑：陈 宏）

中国药房 2023年第34卷第8期 China Pharmacy 2023 Vol. 34 No. 8 · 999 ·